Bermuda vs Saint Kitts and Nevis: The number of people with susceptibility test result for rifampicin
Bermuda
2
in 2021
Saint Kitts and Nevis
0
in 2021
Bermuda rank
143rd
Saint Kitts and Nevis rank
146th
The number of people with susceptibility test result for rifampicin over time
- Bermuda
- Saint Kitts and Nevis
How they compare
Bermuda currently reports 2 against 0 in Saint Kitts and Nevis, a difference of 2.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Saint Kitts and Nevis ahead.
Bermuda ranks 143rd and Saint Kitts and Nevis ranks 146th of 155 countries.
Bermuda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bermuda | Saint Kitts and Nevis | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.33 | 1 | 0.3333 | Bermuda |
| 2020s | 2 | 0.5 | 1.5 | Bermuda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Bermuda or Saint Kitts and Nevis?
- Bermuda, at 2 against 0 in Saint Kitts and Nevis as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Bermuda and Saint Kitts and Nevis?
- 2, with Bermuda ahead.
- How many years of comparable data are there for Bermuda and Saint Kitts and Nevis?
- 5 years are reported by both, from 2017 to 2021.
- How do Bermuda and Saint Kitts and Nevis rank globally for the number of people with susceptibility test result for rifampicin?
- Bermuda ranks 143rd and Saint Kitts and Nevis ranks 146th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.